Study of MOC31-PE in Antigen Positive Carcinomas
NCT01061645
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Carcinoma
Interventions
DRUG:
MOC31-PE
Sponsor
Oslo University Hospital